Basics |
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology.
|
IPO Date: |
October 7, 2015 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$164.59M |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.35 | 3.17%
|
Avg Daily Range (30 D): |
$0.04 | 2.52%
|
Avg Daily Range (90 D): |
$0.04 | 3.10%
|
Institutional Daily Volume |
Avg Daily Volume: |
.67M |
Avg Daily Volume (30 D): |
.66M |
Avg Daily Volume (90 D): |
.73M |
Trade Size |
Avg Trade Size (Sh.): |
151 |
Avg Trade Size (Sh.) (30 D): |
158 |
Avg Trade Size (Sh.) (90 D): |
164 |
Institutional Trades |
Total Inst.Trades: |
1,174 |
Avg Inst. Trade: |
$1.57M |
Avg Inst. Trade (30 D): |
$4.47M |
Avg Inst. Trade (90 D): |
$3.34M |
Avg Inst. Trade Volume: |
.14M |
Avg Inst. Trades (Per Day): |
1 |
Market Closing Trades |
Avg Closing Trade: |
$1.5M |
Avg Closing Trade (30 D): |
$10.84M |
Avg Closing Trade (90 D): |
$6.68M |
Avg Closing Volume: |
142.04K |
|
|
Financials |
|
TTM |
Q1 2025 |
Q4 2024 |
Basic EPS
|
$-1.59
|
$-.12
|
$-1.21
|
Diluted EPS
|
$-1.59
|
$-.12
|
$-1.21
|
Revenue
|
$ 17.78M
|
$ 1.46M
|
$ 9.21M
|
Gross Profit
|
$ 15.29M
|
$ .95M
|
$ 8.51M
|
Net Income / Loss
|
$ -130.21M
|
$ -15.09M
|
$ -96.55M
|
Operating Income / Loss
|
$ -141.09M
|
$ -18.08M
|
$ -99.68M
|
Cost of Revenue
|
$ 2.49M
|
$ .51M
|
$ .71M
|
Net Cash Flow
|
$ -5.48M
|
$ 5.79M
|
$ -23.08M
|
PE Ratio
|
|
|
|
|
|
|